Neurotoxicity Assay (RA-differentiated Human SH-SY5Y cells), Neurite outgrowth SafetyScreen Assay – TW
OVERVIEW
DOCUMENTS/REFERENCES
Biological Information
Background Information:
Neurotoxicity refers to the damage and disruption of nervous system function or structure caused by exogenous compounds, potentially leading to acute or chronic toxic effects, particularly during critical developmental stages. The SH-SY5Y human neuroblastoma cell line has been widely utilized as an in vitro model for neurotoxicity studies due to its adaptability. It can be maintained as proliferative neuroblasts or induced to differentiate into neuron-like cells, mimicking aspects of neuronal function and morphology. This differentiation capability enables assessment of neurotoxicity in both immature and mature neuronal states. As a human-derived neuronal-like model, differentiated SH-SY5Y cells provide a physiologically relevant platform for neurotoxicological screening, supporting the evaluation of drug safety, chemical risk assessment, and mitigation of adverse effects on the nervous system. In this assay, differentiated SH-SY5Y cells are used, and neurite length is assessed to indicate the potential neurotoxicity of the test samples.
Family:
Cell Based Phenotypic
Organism:
Human
Construct Details:
Endogenous
Cell Type:
SH-SY5Y
Assay Information
Assay Type:
Functional
Assay Sub Type:
Cell Based
Functional Mode:
Antagonist
Detection Method:
High-content Imaging
Platform:
HCA
Measured Response:
Fluorescence
Testing Information
Procedure Summary:
SH-SY5Y cells are seeded in the 96-well half area plate and differentiated for 7 days at 37°C, 5% CO₂. Test compound and/or vehicle is then added for an additional 72 hours at 37°C, 5% CO₂. After incubation, the cells are stained with fluorescent dyes. The cell images are acquired by ImageXpress Micro Confocal High-Content Imaging System. Neurite outgrowth is evaluated and analyzed by MetaXpress software. Decrease of neurite outgrowth by 50 percent or more (≥50%) relative to vehicle treated control indicates significant neurotoxicity. 1 μM Brefeldin A is defined as 100% inhibition.
Incubation:
3 d at 37°C
Control Inhibitor:
Brefeldin A
Criteria For Significance:
≥ 50% Decrease of neurite outgrowth relative to vehicle control
Test Concentration / Dose:
Compounds are screened at 10, 3, 1, 0.3, 0.1, 0.03, 0.01 and 0.003 μM
Test Sample Requirements:
75 μl of 10 mM stock or 1 mg (pre-weighed) powder (assuming FW ≦500 and purity 100%)
Minimum Order Quantity:
16
Turnaround Time
Standard:
30 Business Days
Reference Compound Data
Clinical Relevance
Therapeutic Area:
CNS/Addiction/Pain
Additional Information
Brand:
Panlabs
Testing Location:
Taiwan - Taipei
Questions? Contact Us
You can easily get in touch with a Eurofins Discovery Expert or get help from our Customer Service team. Reach out with questions, or to discuss your specific discovery challenges.
